Intranuclear inclusions in a fragile X mosaic male

Dalyir I. Pretto, Michael R. Hunsaker, Christopher L. Cunningham, Claudia M. Greco, Randi J Hagerman, Stephen C Noctor, Deborah A. Hall, Paul J Hagerman, Flora Tassone

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Lack of the fragile X mental retardation protein leads to Fragile X syndrome (FXS) while increased levels of FMR1 mRNA, as those observed in premutation carriers can lead to Fragile X- associated tremor ataxia syndrome (FXTAS). Until recently, FXTAS had been observed only in carriers of an FMR1 premutation (55-200 CGG repeats); however the disorder has now been described in individuals carriers of an intermediate allele (45-54 CGG repeats) as well as in a subject with a full mutation with mosaicism.Here, we report on molecular and clinical data of a male FMR1 mosaic individual with full and premutation alleles. Molecular analysis of FMR1 and FMRP expression in this subject is consistent with a FXS phenotype. We observed reduced expression of FMRP in both peripheral blood and brain leading to the FXS diagnosis. In addition, a dramatic 90% depletion of both FMR1 mRNA and FMRP levels was observed in the blood, as normally observed in FXS cases, and an even greater depletion in the brain. A clinical report of this patient, at age 71, described neurodegenerative signs of parkinsonism that were likely, in retrospect, part of a FXTAS scenario as post-mortem examination shows the presence of intranuclear inclusions, the hallmark pathology of FXTAS.The findings presented in this study indicate co-morbidity for both FXS and FXTAS in this individual carrying both full and premutation FMR1 alleles. In addition, based on symptoms and pathological and molecular evidence, this report suggests the need to redefine the diagnostic criteria of FXTAS.

Original languageEnglish (US)
Article number10
JournalTranslational Neurodegeneration
Volume2
Issue number1
DOIs
StatePublished - May 21 2013

Fingerprint

Intranuclear Inclusion Bodies
Fragile X Syndrome
Alleles
Fragile X Mental Retardation Protein
Messenger RNA
Mosaicism
Brain
Parkinsonian Disorders
Fragile X Tremor Ataxia Syndrome
Autopsy
Pathology
Morbidity
Phenotype
Mutation

Keywords

  • FXS
  • FXTAS
  • Intranuclear inclusions
  • Premutation

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Cognitive Neuroscience

Cite this

Intranuclear inclusions in a fragile X mosaic male. / Pretto, Dalyir I.; Hunsaker, Michael R.; Cunningham, Christopher L.; Greco, Claudia M.; Hagerman, Randi J; Noctor, Stephen C; Hall, Deborah A.; Hagerman, Paul J; Tassone, Flora.

In: Translational Neurodegeneration, Vol. 2, No. 1, 10, 21.05.2013.

Research output: Contribution to journalArticle

Pretto, Dalyir I. ; Hunsaker, Michael R. ; Cunningham, Christopher L. ; Greco, Claudia M. ; Hagerman, Randi J ; Noctor, Stephen C ; Hall, Deborah A. ; Hagerman, Paul J ; Tassone, Flora. / Intranuclear inclusions in a fragile X mosaic male. In: Translational Neurodegeneration. 2013 ; Vol. 2, No. 1.
@article{962ef69157e34064a846791f1b05b6e3,
title = "Intranuclear inclusions in a fragile X mosaic male",
abstract = "Lack of the fragile X mental retardation protein leads to Fragile X syndrome (FXS) while increased levels of FMR1 mRNA, as those observed in premutation carriers can lead to Fragile X- associated tremor ataxia syndrome (FXTAS). Until recently, FXTAS had been observed only in carriers of an FMR1 premutation (55-200 CGG repeats); however the disorder has now been described in individuals carriers of an intermediate allele (45-54 CGG repeats) as well as in a subject with a full mutation with mosaicism.Here, we report on molecular and clinical data of a male FMR1 mosaic individual with full and premutation alleles. Molecular analysis of FMR1 and FMRP expression in this subject is consistent with a FXS phenotype. We observed reduced expression of FMRP in both peripheral blood and brain leading to the FXS diagnosis. In addition, a dramatic 90{\%} depletion of both FMR1 mRNA and FMRP levels was observed in the blood, as normally observed in FXS cases, and an even greater depletion in the brain. A clinical report of this patient, at age 71, described neurodegenerative signs of parkinsonism that were likely, in retrospect, part of a FXTAS scenario as post-mortem examination shows the presence of intranuclear inclusions, the hallmark pathology of FXTAS.The findings presented in this study indicate co-morbidity for both FXS and FXTAS in this individual carrying both full and premutation FMR1 alleles. In addition, based on symptoms and pathological and molecular evidence, this report suggests the need to redefine the diagnostic criteria of FXTAS.",
keywords = "FXS, FXTAS, Intranuclear inclusions, Premutation",
author = "Pretto, {Dalyir I.} and Hunsaker, {Michael R.} and Cunningham, {Christopher L.} and Greco, {Claudia M.} and Hagerman, {Randi J} and Noctor, {Stephen C} and Hall, {Deborah A.} and Hagerman, {Paul J} and Flora Tassone",
year = "2013",
month = "5",
day = "21",
doi = "10.1186/2047-9158-2-10",
language = "English (US)",
volume = "2",
journal = "Translational Neurodegeneration",
issn = "2047-9158",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Intranuclear inclusions in a fragile X mosaic male

AU - Pretto, Dalyir I.

AU - Hunsaker, Michael R.

AU - Cunningham, Christopher L.

AU - Greco, Claudia M.

AU - Hagerman, Randi J

AU - Noctor, Stephen C

AU - Hall, Deborah A.

AU - Hagerman, Paul J

AU - Tassone, Flora

PY - 2013/5/21

Y1 - 2013/5/21

N2 - Lack of the fragile X mental retardation protein leads to Fragile X syndrome (FXS) while increased levels of FMR1 mRNA, as those observed in premutation carriers can lead to Fragile X- associated tremor ataxia syndrome (FXTAS). Until recently, FXTAS had been observed only in carriers of an FMR1 premutation (55-200 CGG repeats); however the disorder has now been described in individuals carriers of an intermediate allele (45-54 CGG repeats) as well as in a subject with a full mutation with mosaicism.Here, we report on molecular and clinical data of a male FMR1 mosaic individual with full and premutation alleles. Molecular analysis of FMR1 and FMRP expression in this subject is consistent with a FXS phenotype. We observed reduced expression of FMRP in both peripheral blood and brain leading to the FXS diagnosis. In addition, a dramatic 90% depletion of both FMR1 mRNA and FMRP levels was observed in the blood, as normally observed in FXS cases, and an even greater depletion in the brain. A clinical report of this patient, at age 71, described neurodegenerative signs of parkinsonism that were likely, in retrospect, part of a FXTAS scenario as post-mortem examination shows the presence of intranuclear inclusions, the hallmark pathology of FXTAS.The findings presented in this study indicate co-morbidity for both FXS and FXTAS in this individual carrying both full and premutation FMR1 alleles. In addition, based on symptoms and pathological and molecular evidence, this report suggests the need to redefine the diagnostic criteria of FXTAS.

AB - Lack of the fragile X mental retardation protein leads to Fragile X syndrome (FXS) while increased levels of FMR1 mRNA, as those observed in premutation carriers can lead to Fragile X- associated tremor ataxia syndrome (FXTAS). Until recently, FXTAS had been observed only in carriers of an FMR1 premutation (55-200 CGG repeats); however the disorder has now been described in individuals carriers of an intermediate allele (45-54 CGG repeats) as well as in a subject with a full mutation with mosaicism.Here, we report on molecular and clinical data of a male FMR1 mosaic individual with full and premutation alleles. Molecular analysis of FMR1 and FMRP expression in this subject is consistent with a FXS phenotype. We observed reduced expression of FMRP in both peripheral blood and brain leading to the FXS diagnosis. In addition, a dramatic 90% depletion of both FMR1 mRNA and FMRP levels was observed in the blood, as normally observed in FXS cases, and an even greater depletion in the brain. A clinical report of this patient, at age 71, described neurodegenerative signs of parkinsonism that were likely, in retrospect, part of a FXTAS scenario as post-mortem examination shows the presence of intranuclear inclusions, the hallmark pathology of FXTAS.The findings presented in this study indicate co-morbidity for both FXS and FXTAS in this individual carrying both full and premutation FMR1 alleles. In addition, based on symptoms and pathological and molecular evidence, this report suggests the need to redefine the diagnostic criteria of FXTAS.

KW - FXS

KW - FXTAS

KW - Intranuclear inclusions

KW - Premutation

UR - http://www.scopus.com/inward/record.url?scp=84883602770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883602770&partnerID=8YFLogxK

U2 - 10.1186/2047-9158-2-10

DO - 10.1186/2047-9158-2-10

M3 - Article

C2 - 23692864

AN - SCOPUS:84883602770

VL - 2

JO - Translational Neurodegeneration

JF - Translational Neurodegeneration

SN - 2047-9158

IS - 1

M1 - 10

ER -